Form D · Biotechnology
MetaVia Inc.
Cambridge, MA · CIK 0001638287
Offering snapshot reported May 15, 2025 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 8, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 15, 2025 | Initial | $10,000,000 | No comparison | 2 | SEC filing |
| Jul 1, 2024 | Initial | $16,998,224 | No comparison | 2 | SEC filing |
| Oct 18, 2021 | Initial | $14,000,002 | No comparison | 12 | SEC filing |
| Feb 1, 2021 | Initial | $10,000,000 | No comparison | 10 | SEC filing |
| Jan 12, 2021 | Initial | $17,030,344 | No comparison | 34 | SEC filing |
| Mar 30, 2017 | Initial | $12,540,704 | No comparison | 26 | SEC filing |
| Apr 27, 2016 | Amendment | $10,601,500 | $5,000,000vs Mar 10, 2016 | 59 | SEC filing |
| Mar 10, 2016 | Amendment | $5,601,500 | $150,500vs Dec 22, 2015 | 53 | SEC filing |
| Dec 22, 2015 | Amendment | $5,451,000 | $2,650,000vs Aug 7, 2015 | 52 | SEC filing |
| Aug 7, 2015 | Amendment | $2,801,000 | $0vs Aug 7, 2015 | 36 | SEC filing |
| Aug 7, 2015 | Initial | $2,801,000 | No comparison | 36 | SEC filing |
| Apr 15, 2015 | Initial | $5,000,000 | No comparison | 46 | SEC filing |
| Apr 8, 2015 | Initial | $2,739,049 | No comparison | 28 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $423K
- Finders' fees
- $0
- Form D file number
- 021-546292
This Form D is being filed solely with respect to the sale of 9,479,345 shares of common stock and 4,605,162 pre-funded warrants to purchase shares of common stock. Includes expected proceeds of up to $4,605.16 from the exercise of the prefunded warrants.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Ladenburg Thalmann & Co. Inc. | 000000505 |
Source: Form D, filed May 15, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Akash Bakshi | Executive |
| Andrew Bartynski | Executive |
| Charles Bisgaier | Director, Executive |
| Mark A. Glickman | Director |
| Lee S. Golden | Executive |
| Jason L. Groves | Director |
| Steve Gullans | Director |
| Stephen Haakenson | Director |
| P. Kent Hawryluk | Director |
| Richard J. Kang | Director, Executive |
| Na Yeon Kim | Director |
| Hyung Heon Kim | Director, Executive |
| Kenneth Kousky | Director |
| Andrew Koven | Director |
| Pedro Lichtinger | Director |
| David Lowenschuss | Executive |
| Nadja Mannowetz | Executive |
| Jeffrey Mathiesen | Executive |
| Margaret Mc Shane | Executive |
| Jeong Gyun Oh | Director |
| Daniela Oniciu | Executive |
| Seth Reno | Executive |
| Michael Salsbury | Director |
| Andy Sassine | Director |
| Nicola Shannon | Executive |
| Mina Sooch | Director, Executive |
| D. Gordon Strickland | Director |
| Douglas J. Swirsky | Director |
| James P. Tursi | Director |
| Marshall H. Woodworth | Executive |
| Amy Zaremba Rabourn | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
545 Concord Avenue Suite 210
Cambridge, MA, 02138
Cambridge, MA, 02138